Literature DB >> 15111011

Targeting eNOS for stroke protection.

Matthias Endres1, Ulrich Laufs, James K Liao, Michael A Moskowitz.   

Abstract

Nitric oxide (NO) generated by endothelial NO synthase (eNOS) plays a crucial role in vascular function and homeostasis. NO possesses vasodilatory, anti-inflammatory, antithrombotic and antiproliferative properties. Augmentation of NO production increases cerebral blood flow, which can lead to neuroprotection during brain ischaemia. Several modalities that upregulate eNOS expression and/or activity have recently been identified, including HMG-CoA reductase inhibitors (statins), steroid hormones, nutrients and physical activity. They all increase NO bioavailability, leading to enhanced cerebral blood flow and protection from ischaemic stroke. Thus, therapeutic modalities that target eNOS not only serve as preventive measures to reduce stroke incidence but also could represent novel treatment strategies for reducing brain injury during cerebral ischaemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15111011     DOI: 10.1016/j.tins.2004.03.009

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  73 in total

1.  Endothelial dysfunction abrogates the efficacy of normobaric hyperoxia in stroke.

Authors:  Hwa Kyoung Shin; Fumiaki Oka; Ji Hyun Kim; Dmitriy Atochin; Paul L Huang; Cenk Ayata
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

2.  Vascular recovery promoted by atorvastatin and simvastatin after experimental intracerebral hemorrhage: magnetic resonance imaging and histological study.

Authors:  Dongmei Yang; Robert A Knight; Yuxia Han; Kishor Karki; Jianfeng Zhang; Christopher Ding; Michael Chopp; Donald M Seyfried
Journal:  J Neurosurg       Date:  2010-08-20       Impact factor: 5.115

3.  Coactivation of NMDA receptors by glutamate and D-serine induces dilation of isolated middle cerebral arteries.

Authors:  Jillian L LeMaistre; Samuel A Sanders; Michael J Stobart; Lingling Lu; J David Knox; Hope D Anderson; Christopher M Anderson
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-09       Impact factor: 6.200

4.  Unexpected binding modes of nitric oxide synthase inhibitors effective in the prevention of a cerebral palsy phenotype in an animal model.

Authors:  Silvia L Delker; Haitao Ji; Huiying Li; Joumana Jamal; Jianguo Fang; Fengtian Xue; Richard B Silverman; Thomas L Poulos
Journal:  J Am Chem Soc       Date:  2010-04-21       Impact factor: 15.419

Review 5.  Neuroprotection for ischemic stroke: past, present and future.

Authors:  Myron D Ginsberg
Journal:  Neuropharmacology       Date:  2008-03-04       Impact factor: 5.250

Review 6.  Experimental models, neurovascular mechanisms and translational issues in stroke research.

Authors:  E H Lo
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

7.  High doses of simvastatin upregulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase.

Authors:  Qing Wang; Wee Lee Ting; Hongyuan Yang; Peter T-H Wong
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

8.  Inhaled nitric oxide protects males but not females from neonatal mouse hypoxia-ischemia brain injury.

Authors:  Changlian Zhu; Yanyan Sun; Jianfeng Gao; Xiaoyang Wang; Nikolaus Plesnila; Klas Blomgren
Journal:  Transl Stroke Res       Date:  2012-10-20       Impact factor: 6.829

9.  Structural basis for isoform-selective inhibition in nitric oxide synthase.

Authors:  Thomas L Poulos; Huiying Li
Journal:  Acc Chem Res       Date:  2012-10-02       Impact factor: 22.384

10.  The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia.

Authors:  Sunghee Cho; Eun-Mi Park; Maria Febbraio; Josef Anrather; Laibaik Park; Gianfranco Racchumi; Roy L Silverstein; Costantino Iadecola
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.